Who are Hympavzi's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Eliquis, Xarelto, Heparin Sodium In Plastic Container, Oroxid®, LMWH+Folic acid, Intermediate dose dalteparin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/chembl-chembl3990039.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Hympavzi — Competitive Intelligence Brief

Hympavzi (MARSTACIMAB) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal Antibody. Area: Rare Disease.

marketed Monoclonal Antibody Factor Xa Rare Disease Monoclonal antibody Live · refreshed every 30 min

Target snapshot

Hympavzi (MARSTACIMAB) — Pfizer Inc. Hympavzi works by binding to Factor Xa, a protein involved in blood clotting.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Hympavzi TARGET	MARSTACIMAB	Pfizer Inc	marketed	Monoclonal Antibody	Factor Xa	2025-01-01
Eliquis	apixaban	Bristol-Myers Squibb	marketed	Factor Xa inhibitor	Factor Xa (FXa)	2012-01-01
Xarelto	rivaroxaban	Johnson & Johnson	marketed	Direct Factor Xa Inhibitor	Factor Xa (FXa)	2011-01-01
Heparin Sodium In Plastic Container	Heparin Sodium	Fresenius Kabi	marketed	Anti-coagulant	Antithrombin III, Factor Xa, Factor IIa	1939-01-01
Oroxid®	Oroxid®	Charles University, Czech Republic	marketed	Direct Factor Xa inhibitor	Factor Xa
LMWH+Folic acid	LMWH+Folic acid	Omar Mamdouh Shaaban	marketed	Anticoagulant combination with vitamin supplement	Factor Xa, Thrombin (LMWH component); Dihydrofolate reductase (folic acid component)
Intermediate dose dalteparin	Intermediate dose dalteparin	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	marketed	Low-molecular-weight heparin (LMWH)	Antithrombin III (indirect); Factor Xa and Thrombin (downstream targets)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2034-02-17 — Xarelto · 9539218 · Method of Use · US
2034-08-17 — Xarelto · 9539218*PED · Compound · US

Sponsor landscape (Monoclonal Antibody class)

Pfizer · 3 drugs in this class
National Medical Research Center for Children's Health, Russian Federation · 1 drug in this class
Pfizer Inc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Hympavzi — Competitive Intelligence Brief. https://druglandscape.com/ci/chembl-chembl3990039. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab